Economic Evaluation of Evusheld® for Preexposure Prevention of COVID-19 in High-Risk Populations: Early Evidence from Thailand

The introduction of Coronavirus disease 2019 (COVID-19) vaccines urged all Thais to seek prevention of serious illness and death from COVID-19. However, immunocompromised individuals might not be able to achieve an efficient immune response from these vaccines. This study aimed to evaluate the cost-effectiveness and budget impact of introducing Evusheld® (tixagevimab plus cilgavimab) for three patient groups—organ transplant, autoimmune disease, and dialysis patients, from the Thai government perspective.

Find out the early evidence in Thailand at https://link.springer.com/article/10.1007/s40258-023-00796-7#Sec16